CASC19 and Alzheimer disease: In this community‐based cohort of CU adults, we found higher level of p‐tau181/Aβ42, and a biomarker pattern of higher level of p‐tau181/Aβ42 along with lower level of Aβ42/Aβ40 (i.e., PCA2), predicted the development of incident clinical AD.